MCID: HYP043
MIFTS: 46

Hyperandrogenism

Categories: Endocrine diseases

Aliases & Classifications for Hyperandrogenism

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 12 52 42 14 69
Hyperandrogenization Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11613
MeSH 42 D017588
SNOMED-CT 64 237793004
UMLS 69 C0206081

Summaries for Hyperandrogenism

MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to mullerian aplasia and hyperandrogenism and hyperandrogenism due to cortisone reductase deficiency. An important gene associated with Hyperandrogenism is WNT4 (Wnt Family Member 4), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Glucose / Energy Metabolism. The drugs Cyproterone Acetate and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and immune system

Wikipedia : 72 Hyperandrogenism, also known as androgen excess, is a medical condition characterized by excessive... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
id Related Disease Score Top Affiliating Genes
1 mullerian aplasia and hyperandrogenism 12.2
2 hyperandrogenism due to cortisone reductase deficiency 11.8
3 hair-an syndrome 11.7
4 polycystic ovary syndrome 11.3
5 glucocorticoid resistance 11.0
6 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 11.0
7 cortisone reductase deficiency 10.9
8 cortisone reductase deficiency 2 10.7
9 brachyolmia 4 with mild epiphyseal and metaphyseal changes 10.7
10 diabetes mellitus, insulin-resistant, with acanthosis nigricans 10.7
11 mayer-rokitansky-kuster-hauser syndrome 10.7
12 cortisone reductase deficiency 1 10.7
13 testotoxicosis 10.7
14 46,xx gonadal dysgenesis epibulbar dermoid 10.7 CYP21A2 HSD3B2
15 intellectual deficit buenos-aires type 10.7 INS INSR
16 vaginal discharge 10.6 SHBG WNT4
17 selenium poisoning 10.6 IGF1 INS
18 cleft lip and palate malrotation cardiopathy 10.6 CYP21A2 POMC
19 monosomy 13q34 10.5 CYP21A2 POMC
20 cutis laxa 10.5 INS POMC
21 endometriosis 10.5 PRL SHBG
22 prolactin producing pituitary tumor 10.4 IGF1 POMC
23 aortic valve atresia 10.4 POMC PRL
24 mucinoses 10.4 INS INSR SHBG
25 obesity 10.4
26 olfactory nerve neoplasm 10.4 POMC PRL
27 osteoclast-like giant cell neoplasm of the pancreas 10.4 POMC PRL
28 paroxysmal nonkinesigenic dyskinesia 2 10.4 IGFBP1 INS
29 hypodermyasis 10.4 POMC SHBG
30 group b strep disease in newborns 10.4 INS PRL
31 hyperlipoproteinemia, type ib 10.3 IGF1 INS INSR
32 antidepressant type abuse 10.3 INS INSR SHBG
33 glomerulosclerosis, focal segmental, 1 10.3 IGF1 INS INSR
34 dressler's syndrome 10.3 CYP21A2 POMC
35 skin meningioma 10.3 INS PRL SHBG
36 conjunctival vascular disease 10.3 INS POMC SHBG
37 fetal parvovirus syndrome 10.3 IGF1 INS INSR
38 actinobacillosis 10.3 POMC PRL
39 maturity-onset diabetes of the young, type 10 10.3 IGFBP1 INS SHBG
40 prostate leiomyoma 10.2 GNRH1 PRL
41 acanthosis nigricans 10.2
42 adenomatoid tumor 10.2 GNRH1 PRL
43 adrenal cortex disease 10.2 CYP21A2 POMC PRL
44 anovulation 10.2
45 plague 10.2 IGF1 PRL SHBG
46 hypertensive encephalopathy 10.2 INS POMC PRL
47 pituitary adenoma, prolactin-secreting 10.2 IGF1 PRL
48 neurogenic arthropathy 10.2 IGF1 INS POMC
49 complement component 8 deficiency 10.2 GNRH1 IGF1
50 chondroma 10.2 IGF1 INS POMC

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.7 IGF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.7 IGF1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 CYP21A2 IGF1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.7 INSR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.7 IGF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.7 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.7 IGF1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.7 INSR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.7 CYP21A2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.7 SHBG
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.7 IGF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.7 IGF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.7 CYP21A2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.7 CYP21A2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.7 INSR SHBG CYP21A2 IGF1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.7 IGF1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.7 INSR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.7 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.7 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.7 IGF1

MGI Mouse Phenotypes related to Hyperandrogenism:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.02 PRL WNT4 CYP19A1 GNRH1 IGF1 IGFBP1
2 endocrine/exocrine gland MP:0005379 10.01 CYP19A1 GNRH1 IGF1 INS INSR POMC
3 integument MP:0010771 9.87 CYP19A1 GNRH1 IGF1 INS POMC PRL
4 adipose tissue MP:0005375 9.83 CYP19A1 IGF1 INS INSR POMC
5 liver/biliary system MP:0005370 9.8 PRL CYP19A1 GNRH1 IGFBP1 INS INSR
6 nervous system MP:0003631 9.76 CYP19A1 GNRH1 IGF1 INS INSR POMC
7 renal/urinary system MP:0005367 9.5 CYP19A1 GNRH1 IGF1 INS INSR POMC
8 reproductive system MP:0005389 9.23 CYP17A1 CYP19A1 GNRH1 IGF1 INS INSR

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
3
Ethinyl Estradiol Approved Phase 4,Phase 2 57-63-6 5991
4
Drospirenone Approved Phase 4 67392-87-4 68873
5
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
6
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
9
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
10
Liraglutide Approved Phase 4 204656-20-2 44147092
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
13
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
14
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
16
Resveratrol Experimental, Investigational Phase 4,Phase 3,Phase 1 501-36-0 445154
17
Enclomiphene Investigational Phase 4,Phase 3,Phase 2 15690-57-0
18 Androgen Antagonists Phase 4,Phase 2
19 Androgens Phase 4,Phase 3,Phase 2,Phase 1
20 Contraceptive Agents Phase 4,Phase 2
21 Contraceptive Agents, Male Phase 4
22
Cyproterone Phase 4 2098-66-0 5284537
23 Estradiol 17 beta-cypionate Phase 4,Phase 2
24 Estradiol 3-benzoate Phase 4,Phase 2
25 Estradiol valerate Phase 4,Phase 2 979-32-8
26 Estrogens Phase 4,Phase 3,Phase 2
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Polyestradiol phosphate Phase 4,Phase 2
31 Antioxidants Phase 4,Phase 3
32 Contraceptives, Oral Phase 4,Phase 2
33 Contraceptives, Oral, Combined Phase 4,Phase 2
34 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
35 diuretics Phase 4,Phase 2
36 Diuretics, Potassium Sparing Phase 4,Phase 2
37 Drospirenone and ethinyl estradiol combination Phase 4
38 Hemostatics Phase 4
39 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2
40 Mineralocorticoids Phase 4,Phase 2
41 Natriuretic Agents Phase 4,Phase 2
42 Protective Agents Phase 4,Phase 3
43 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Estrogen Antagonists Phase 4,Phase 3,Phase 2
45 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 3
48 Incretins Phase 4
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 111)

id Name Status NCT ID Phase Drugs
1 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
4 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
5 Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions Completed NCT01626443 Phase 4
6 Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos. Completed NCT01896492 Phase 4 NAC
7 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
8 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
9 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
10 Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed NCT00640224 Phase 4 rosiglitazone;drospirenone/ethinyl estradiol
11 Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
12 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Recruiting NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
13 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
14 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Recruiting NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
15 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Recruiting NCT01721915 Phase 4 Vitamin D supplementation;Placebo
16 Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Unknown status NCT01782911 Phase 3
17 Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study Unknown status NCT02133755 Phase 3 Bromocriptine
18 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
19 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
20 Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS Completed NCT01482286 Phase 3 Metformin
21 The Adrenal Contribution to Androgen Production in Girls During Puberty Completed NCT01062568 Phase 3 Adrenocorticotropin;Dexamethasone
22 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) Completed NCT00747617 Phase 3 recombinant human chorionic gonadotropin
23 Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Completed NCT01961336 Phase 3 Testosterone
24 Obesity in Children and Adolescents: Associated Risks and Early Intervention Completed NCT01677923 Phase 3 Metformin
25 Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Recruiting NCT03135301 Phase 3 letrozole plus metformin;letrozole
26 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2 leuprolide;Ethinyl estradiol/norethindrone
27 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women Completed NCT00704912 Phase 2 Orlistat/Meal Replacement/Lifestyle Modification;Loestrin 1/20;Combination of treatments
28 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
29 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia Completed NCT01859312 Phase 2 Hydrocortisone (Solucortef)
30 Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients Completed NCT02562664 Phase 2 CC;Placebo tablets;Metformin
31 Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
32 Acupuncture or Metformin for Insulin Resistance in Women With PCOS Recruiting NCT02647827 Phase 2 Metformin
33 Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome Recruiting NCT02644304 Phase 2 Clomiphene citrate;Cabergoline
34 Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome Recruiting NCT03152591 Phase 2 LIK066;Placebo
35 Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant Enrolling by invitation NCT02523898 Phase 2 metformine;placebo;clomiphene citrate
36 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Not yet recruiting NCT03229408 Phase 2 Salsalate
37 Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome Completed NCT01457209 Phase 1
38 Time Course of Waking Versus Sleep-associated Luteinizing Hormone (LH) Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia Recruiting NCT00929006 Phase 1 Micronized progesterone suspension;Placebo
39 Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone Recruiting NCT01428089 Phase 1 Progesterone;Placebo
40 Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006) Active, not recruiting NCT01602679 Phase 1 oral micronized progesterone suspension;Placebo
41 Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) Terminated NCT01489319 Phase 1 Salsalate;Salsalate
42 Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425
43 Meal Timing on Glucose and Hyperandrogenism in PCOS Women Unknown status NCT01711476
44 Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome Unknown status NCT00784615
45 Metabolic Disorders in Polycystic Ovarian Syndrome Unknown status NCT00172523
46 The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome Unknown status NCT02126592
47 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome Unknown status NCT00665171
48 Long Acting GnRH Antagonist in PCOS Women Undergoing IVF Unknown status NCT02084940 GnRH antagonist depot Degarelix
49 Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine Unknown status NCT01116167 Letrozole -Berberine;Letrozole;Berberine
50 The Role of Insulin Resistance in PCOS Unknown status NCT00173043

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

MalaCards organs/tissues related to Hyperandrogenism:

39
Ovary, Skin, Testes, Bone, Liver, Hypothalamus, Pituitary

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 644)
id Title Authors Year
1
Hyperandrogenism in adolescent girls: relationship with the somatotrophic axis. ( 28593921 )
2017
2
A peel-off facial mask comprising myoinositol and trehalose-loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy. ( 28342238 )
2017
3
An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients. ( 28125989 )
2017
4
Animal models of hyperandrogenism and ovarian morphology changes as features of polycystic ovary syndrome: a systematic review. ( 28183310 )
2017
5
Expression of AKT1 along with AKT2 in granulosa-lutein cells of hyperandrogenic PCOS patients. ( 28271235 )
2017
6
The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model. ( 28572510 )
2017
7
Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China. ( 28413474 )
2017
8
Effect of TNF-I+ on Molecules Related to the Insulin Action in Endometrial Cells Exposed to Hyperandrogenic and Hyperinsulinic Conditions Characteristics of Polycystic Ovary Syndrome. ( 28946816 )
2017
9
Hyperandrogenism in a postmenopausal woman: a rare case of ectopic adrenal cortical gland. ( 28102088 )
2017
10
Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. ( 28724177 )
2017
11
Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. ( 28089571 )
2017
12
Treatment of hyperandrogenism in women with ethinylestradiol and cyproteroneacetate. ( 28540758 )
2017
13
Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS. ( 28912337 )
2017
14
The prevalence of non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Russian women with hyperandrogenism. ( 28669219 )
2017
15
Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. ( 28575537 )
2017
16
Prevalence of Prediabetes Risk in Offspring Born to Mothers with Hyperandrogenism. ( 28111236 )
2017
17
Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype? ( 28649885 )
2017
18
Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. ( 28370150 )
2017
19
The Distribution of Stroma and Antral Follicles Differs between Insulin-Resistance and Hyperandrogenism-Related Polycystic Ovarian Syndrome. ( 28620353 )
2017
20
Transient hyperandrogenism in 2 preterm twins with exposure to antiretrovirals. ( 28864089 )
2017
21
Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. ( 27756332 )
2016
22
Synchronous Ileal Neuroendocrine Tumor and Ovarian Steroid Cell Tumor Present in a Female With Hyperandrogenism. ( 27167674 )
2016
23
Ethics of Regulating Competition for Women with Hyperandrogenism. ( 26832978 )
2016
24
The 2015 Pediatric Endocrine Society Ethics Symposium: Controversies Regarding 'Gender Verification' of Elite Female Athletes - Sex Testing to Hyperandrogenism. ( 26918844 )
2016
25
Adrenal Hyperandrogenism and Polycystic Ovary Syndrome. ( 27510480 )
2016
26
Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. ( 26951881 )
2016
27
Metformin for women with hyperandrogenic anovulation. ( 26906093 )
2016
28
Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. ( 26890011 )
2016
29
Reply: Metformin for women with hyperandrogenic anovulation. ( 26906091 )
2016
30
Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome. ( 27336356 )
2016
31
Hyperandrogenism rule no longer in play at Rio Olympics. ( 27503334 )
2016
32
Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism. ( 27060006 )
2016
33
The Relationship Between Hearing Thresholds and Hyperandrogenism in Polycystic Ovary Syndrome. ( 27846196 )
2016
34
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. ( 27459230 )
2016
35
Postmenopausal hyperandrogenism: the under-recognized value of inhibins. ( 27278937 )
2016
36
A novel insulin receptor mutation in an adolescent with acanthosis nigricans and hyperandrogenism. ( 27505086 )
2016
37
Gestational Hyperandrogenism in Developmental Programming. ( 27967205 )
2016
38
Ovarian Leydig cell hyperplasia as a rare cause of hair loss in a postmenopausal female patient: a case report and diagnostic approach toward postmenopausal hyperandrogenism. ( 26950172 )
2016
39
Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. ( 27179108 )
2016
40
Postmenopausal hyperandrogenism of ovarian origin: A clinicopathologic study of five cases. ( 28096644 )
2016
41
Hyperandrogenism Decreases GRP78 Protein Level and Glucose Uptake in Human Endometrial Stromal Cells. ( 26614265 )
2016
42
Prostate-Specific Antigen as a Marker of Hyperandrogenism in Women and Its Implications for Antidoping. ( 27259815 )
2016
43
Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective. ( 26964728 )
2016
44
A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans. ( 27746646 )
2016
45
Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage In Normal Weight Polycystic Ovary Syndrome Women. ( 27571186 )
2016
46
Evidence-based approach to cutaneous hyperandrogenism in women. ( 26138647 )
2015
47
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women. ( 26199450 )
2015
48
Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome. ( 25637475 )
2015
49
Manifestation of Hyperandrogenism in the Continuous Light Exposure-Induced PCOS Rat Model. ( 26064969 )
2015
50
Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. ( 25610004 )
2015

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 12.43 IGF1 INS INSR PRL WNT4
2 12.2 CYP19A1 IGFBP1 INS INSR
3
Show member pathways
12.17 IGF1 INS INSR WNT4
4
Show member pathways
11.92 IGF1 INS INSR
5
Show member pathways
11.85 IGF1 INS INSR
6 11.68 IGF1 INS INSR
7 11.64 IGF1 INS WNT4
8 11.6 CYP21A2 HSD3B2 POMC
9
Show member pathways
11.3 CYP17A1 CYP19A1 CYP21A2 HSD3B2 POMC
10
Show member pathways
11.28 CYP17A1 CYP19A1 HSD3B2
11
Show member pathways
11.26 CYP17A1 CYP19A1 CYP21A2 HSD3B2
12 11.2 INS INSR PRL
13 11.04 INS INSR
14 11 IGF1 INS INSR
15 10.88 IGF1 IGFBP1
16
Show member pathways
10.87 CYP17A1 CYP21A2
17 10.8 CYP17A1 CYP19A1 HSD3B2 IGF1 INS INSR
18 10.78 GNRH1 SHBG

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 GNRH1 IGF1 IGFBP1 INS POMC PRL
2 endosome lumen GO:0031904 8.96 INS PRL

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.81 IGF1 IGFBP1 INS PRL
2 positive regulation of MAPK cascade GO:0043410 9.72 IGF1 INS INSR
3 insulin receptor signaling pathway GO:0008286 9.71 IGFBP1 INS INSR
4 positive regulation of DNA replication GO:0045740 9.65 IGF1 INS INSR
5 positive regulation of glucose import GO:0046326 9.63 IGF1 INS INSR
6 activation of protein kinase B activity GO:0032148 9.61 IGF1 INS INSR
7 regulation of multicellular organism growth GO:0040014 9.6 IGF1 PRL
8 female gonad development GO:0008585 9.59 CYP19A1 WNT4
9 sex differentiation GO:0007548 9.58 CYP17A1 WNT4
10 adrenal gland development GO:0030325 9.58 INSR WNT4
11 positive regulation of mitotic nuclear division GO:0045840 9.58 IGF1 INS INSR
12 glucose homeostasis GO:0042593 9.57 INS INSR
13 male sex determination GO:0030238 9.56 GNRH1 INSR
14 sterol metabolic process GO:0016125 9.54 CYP17A1 CYP19A1 CYP21A2
15 positive regulation of respiratory burst GO:0060267 9.52 INS INSR
16 positive regulation of glycolytic process GO:0045821 9.5 IGF1 INS INSR
17 mineralocorticoid biosynthetic process GO:0006705 9.49 CYP21A2 HSD3B2
18 steroid biosynthetic process GO:0006694 9.46 CYP17A1 CYP19A1 CYP21A2 HSD3B2
19 positive regulation of glycogen biosynthetic process GO:0045725 9.43 IGF1 INS INSR
20 androgen biosynthetic process GO:0006702 9.13 CYP17A1 HSD3B2 WNT4
21 glucocorticoid biosynthetic process GO:0006704 8.8 CYP17A1 CYP21A2 HSD3B2

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.58 CYP17A1 CYP19A1 CYP21A2
2 heme binding GO:0020037 9.54 CYP17A1 CYP19A1 CYP21A2
3 steroid binding GO:0005496 9.46 CYP21A2 SHBG
4 steroid hydroxylase activity GO:0008395 9.43 CYP19A1 CYP21A2
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.43 CYP17A1 CYP19A1 CYP21A2
6 insulin-like growth factor I binding GO:0031994 9.32 IGFBP1 INSR
7 insulin-like growth factor II binding GO:0031995 9.16 IGFBP1 INSR
8 insulin-like growth factor receptor binding GO:0005159 9.13 IGF1 INS INSR
9 hormone activity GO:0005179 9.02 GNRH1 IGF1 INS POMC PRL

Sources for Hyperandrogenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....